Covid 19 Research using Clinical Trials (Home Page)
Report for D060085: Coinfection NIH
(Synonyms: Coinfection)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug353 | Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days Wiki | 1.00 |
| drug853 | Placebo 250 cc 24 hours continuous infusion for 15 days Wiki | 1.00 |
| drug439 | FilmArray Pneumonia Wiki | 1.00 |
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Co-infections in COVID-19 Critically Ill and Antibiotic Management
International guidelines suggest the administration of empirical broad-spectrum antibiotics for suspected bacterial co-infection in COVID-19 critically ill. However, data on associated respiratory infections is rare and antimicrobial stewardship interventions promoting antibiotic savings are non-existent in this context. The main objectives of the trial are: to evaluate the rate of co-infections among COVID-19 critically ill to evaluate the added value of a a rapid molecular diagnostic tool (FA-PNEU) to detect the presence of co-infecting pathogens in order to rapidly tailor the patient's antibiotic treatment
NCT04382092 COVID-19 Diagnostic Test: FilmArray Pneumonia MeSH:Coinfection
Primary Outcomes
Description: COVID-19 infections with additional bacteria/viruses identified through FA-PNEU testing
Measure: % of COVID-19 co-infections Time: through study completion, an average of 1 monthSecondary Outcomes
Description: The rapid FA results could allow a fast modification of the empirical antibiotherapy. This percentage will be measured.
Measure: % of antibiotic switches following FA results Time: through study completion, an average of 1 month